Updated:
Aspira Women's Health
Aspira Women's Health, led by CEO Nicole Sandford, develops blood-based diagnostics for gynecologic conditions after losing its core test in 2023.
Aspira Women's Health
Aspira Women's Health was founded in 1993 and has operated under several names, including Vermillion, before rebranding. The firm is not a traditional asset manager but an operating company developing blood-based diagnostic tests for gynecologic cancers and conditions. Its historical core product was OVA1, an FDA-cleared test for ovarian cancer risk assessment. That test's FDA clearance was revoked in 2023 for non-compliance with premarket approval requirements, a terminal blow to its legacy revenue stream. The company's current strategy centers on OvaWatch, a test for ovarian cancer risk in women with adnexal masses, and EndoCheck, a blood test under development for endometriosis. Aspira does not deploy capital into portfolios or funds; it consumes it in R&D and commercial operations. The firm sustained itself through 2023 and 2024 via a series of dilutive equity financings, including a registered direct offering priced at-the-market. The company has no meaningful geographic diversification beyond the United States laboratory market. CEO Nicole Sandford joined Aspira in 2022 from a corporate governance and turnaround background, not a clinical or large-scale diagnostic launch history. The firm eliminated its executive chairman role in March 2025 to streamline costs. As of early 2026, the company maintains a lab in Austin, Texas, and has outsourced certain R&D functions. Aspira does not operate a philanthropic foundation or adjacent investment vehicle. In December 2024 the company completed a 1-for-15 reverse stock split to regain NASDAQ listing compliance (per the firm's SEC filings). The structural differentiator — which is also the structural vulnerability — is that Aspira is a public micro-cap life sciences company required to fund ongoing operations entirely through the equity markets without a diversified parent or endowment backstop. Every pivotal trial milestone and every quarterly cash balance is a fundraising event. There is no permanent capital, no captive patient flow, and no second product line to fall back on if EndoCheck fails to gain clearance or adoption.
General information
Firm type
Asset Manager
Year founded
1993
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Austin
Corporate office
Austin, TX, United States
Principals
Nicole Sandford
CEO and Director
Torsten Hoof
Chief Financial Officer
Sector focus
Frequently asked questions
What happened to Aspira's original ovarian cancer test OVA1?
OVA1 was Aspira's foundational FDA-cleared product. In 2023 the FDA revoked its premarket approval after the company failed to comply with post-approval study requirements. The revocation eliminated Aspira's primary commercial revenue stream and forced a complete strategic pivot toward OvaWatch and the EndoCheck pipeline program.
What is EndoCheck and why does it matter for Aspira's survival?
EndoCheck is a blood-based test under development to aid in the diagnosis of endometriosis, a condition affecting roughly 10% of reproductive-age women. The test has no FDA clearance yet and represents Aspira's largest addressable market opportunity. Failure to achieve FDA clearance or secure reimbursement for EndoCheck would likely exhaust the company's financing runway.
How does Aspira fund its operations without a stable product revenue base?
Aspira funds operations through sales of equity securities — primarily registered direct offerings and at-the-market programs — rather than retained earnings or debt. The firm's cash runway is a function of its quarterly burn rate and its ability to access public equity markets, which are sensitive to dilution and the micro-cap biotech environment.
Does Aspira Women's Health operate any investment vehicles or manage outside capital?
No. Aspira Women's Health is an operating diagnostics company, not an asset manager or family office. It consumes capital for research, clinical trials, and commercialization. It does not deploy capital into third-party funds, direct investments, or co-investment vehicles.
Who leads the company and what relevant experience do they bring?
Nicole Sandford has served as CEO and a director since 2022. Her background includes corporate governance, audit, and turnaround advisory roles. She does not have a publicly known track record of bringing a major diagnostic product from clinical validation through FDA clearance and broad commercial adoption.
Where does Aspira provide its laboratory services?
Aspira's laboratory operations are based in Austin, Texas. The company's commercial efforts are concentrated in the United States, with no known international laboratory facilities or distribution partnerships for its testing services.
What is the company's current stock exchange listing status?
Aspira trades on the NASDAQ Capital Market under the ticker AWH. The company conducted a 1-for-15 reverse stock split in December 2024 to cure a bid-price deficiency and maintain its listing. Continued listing is contingent on meeting all NASDAQ quantitative requirements.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: